Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60Leukemia 32Gastrointestinal Stromal Tumors 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Chronic-Phase 21Blast Crisis 9Philadelphia Chromosome 8Neoplasm Metastasis 8Melanoma 8Lung Neoplasms 8Brain Neoplasms 7Sarcoma 6Prostatic Neoplasms 6Neoplasms 6Recurrence 5Ovarian Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Small Cell Lung Carcinoma 4Primary Myelofibrosis 4Polycythemia Vera 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Acute 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myeloid 4Dermatofibrosarcoma 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms 4Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3

Interventions

Cisplatin 28Pemetrexed 22Gemcitabine 10Nivolumab 9Carboplatin 9pembrolizumab 8tremelimumab 5durvalumab 5atezolizumab 5Radiotherapy 5Doxorubicin 4Chemotherapy, Adjuvant 4Vinorelbine 3Ipilimumab 3Bortezomib 3Bevacizumab 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2sodium thiosulfate 2sargramostim 2niraparib 2nintedanib 2liposomal doxorubicin 2lenvatinib 2defactinib 2cemiplimab 2cediranib 2amatuximab 2Trabectedin 2Neoadjuvant Therapy 2Mitomycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mesothelioma, Malignant × Imatinib Mesylate × Clear all
NCT02303899 2021-01-22

Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma

Istituto Clinico Humanitas

Phase 2 Completed
22 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡